Mibefradil, a novel therapy for glioblastoma multiforme: Cell cycle synchronization and interlaced therapy in a murine model

Journal of Neuro-Oncology

Volumn 111, Issue 2, 2013, Pages 97-102

  Keir, Stephen T ^a   Friedman, Henry S ^a   Reardon, David A ^a   Bigner, Darell D ^a   Gray, Lloyd A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Tau Therapeutics LLC   (United States)

Author keywords

Glioblastoma; Proliferation; T type calcium channels

Indexed keywords

MIBEFRADIL; TEMOZOLOMIDE; ALKYLATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SYNCHRONIZATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; MONOTHERAPY; MOUSE; MURINE MODEL; NONHUMAN; TREATMENT FAILURE; TREATMENT RESPONSE; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CYCLE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; HUMAN; KAPLAN MEIER METHOD; METHODOLOGY; SKIN TUMOR; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CALCIUM CHANNEL BLOCKERS; CELL CYCLE; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MIBEFRADIL; MICE; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84876881311     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0995-0     Document Type: Article

References (20)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
2. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
3. Darkes MJM, Plosker GL, Jarvis B (2002) Temozolomide: a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am J Cancer 1:55-80
4. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275-287
5. Lory P, Bidaud I, Chemin J (2006) T-type calcium channels in differentiation and proliferation. Cell Calcium 40:135-146
6. Gray LS, Perez-Reyes E, Gomora JC et al (2004) The role of voltage gated T-type Ca2+ channel isoforms in mediating "capacitative" Ca2+ entry in cancer cells. Cell Calcium 36:489-497
7. Munaron L, Antoniotti S, Fiorio Pla A, Lovisolo D (2004) Blocking Ca2+entry: a way to control cell proliferation. Curr Med Chem 11:1533-1543
8. Clozel JP, Ertel EA, Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl 15:S17-S25
9. Panner A, Cribbs LL, Zainelli GM, Origitano TC, Singh S, Wurster RD (2005) Variation of T-type calcium channel protein expression affects cell division of cultured tumor cells. Cell Calcium 37:105-119
10. Friedman HS, Colvin OM, Skapek SX et al (1988) Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48:4189-4195
11. Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM (1999) Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - preclinical studies in a nude mouse model. Neurosurgery 45:1208-1214; discussion 14-15
12. Gehan EA (1965) A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika 52:203-223
13. Po AL, Zhang WY (1998) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351:1829-1830
14. Kobrin I, Charlon V, Lindberg E, Pordy R (1997) Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. Am J Cardiol 80:40C-46C
15. Schmitt R, Clozel JP, Iberg N, Buhler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 15:1161-1165
16. Schmitt R, Clozel JP, Iberg N, Buhler FR (1996) Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition. Cardiovasc Drugs Ther 10:101-105
17. Schmitt R, Clozel JP, Iberg N, Buhler FR (1995) Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 15:1161-1165
18. Clozel JP, Ertel EA, Ertel SI (1999) Voltage-gated T-type Ca 2+ channels and heart failure. Proc Assoc Am Phys 111:429-437
19. Vokes EE (1994) The promise of biochemical modulation in combined modality therapy. Semin Oncol 21:29-33
20. Camplejohn RS (1980) A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy. Cell Tissue Kinet 13:327-335